New stock news | Ko Li Second Submission to Hong Kong Exchange

date
13:44 30/06/2026
avatar
GMT Eight
According to the disclosure from Hong Kong Stock Exchange on June 30th, Ke Li Limited (referred to as Ke Li) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC being its exclusive sponsor. The company had previously submitted a listing application to the Hong Kong Stock Exchange on December 18, 2025.
According to the disclosure on June 30 by the Hong Kong Stock Exchange, Ke Li Limited (referred to as "Ke Li") has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with CICC as its exclusive sponsor. The company had previously submitted a listing application to the Hong Kong Stock Exchange on December 18, 2025. According to data from Frost & Sullivan, based on 2025 revenue, Ke Li ranks in the top ten in sales, promotion, and marketing in China Meheco Group, with a market share of approximately 2.0%. According to the same data, based on 2025 revenue calculations, the company is the largest pediatric pharmaceutical sales, promotion, and marketing service provider in China, with a market share of approximately 17.0%.